Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, cellular therapies to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
Medigene’s T-cell-focused immunotherapies have the potential to treat a wide range of cancers in various stages. Our strategy is to advance our proprietary clinical development programs, beginning with the field of hematological malignancies, and to offer further development options, including solid tumors, to selected partners.
Based on our deep science acumen, we aim to further develop and commercialize innovative immunotherapies in areas of high unmet medical need, not only on our own, but also in collaboration with other companies.
- Focus on T-cell-directed immunotherapies
- T cell receptor-modified T cell (TCR-T)-therapy MDG1011 for indications with high unmet medical need like AML, MM and MDS in clinical Phase I/II trial
- Dendritic cell vaccines (DCs) in ongoing clinical phase I/II trial
- Over 100 employees with expertise in immunotherapy and pharmaceutical development
- Headquartered in Martinsried near Munich (Germany), with US-office in San Diego, California
- Listed on Frankfurt Stock Exchange: MDG1; ISIN DE000A1X3W00
|1994||Medigene founded as Munich Gene Center spin-off|
|2000||Medigene IPO listed on the Frankfurt Stock Exchange|
|2001||Medigene acquired US biotechnology company NeuroVir, Inc.|
|2004||Medigene acquired products and technology of Munich Biotech AG|
|2004||Medigene received first market approval for cancer drug Eligard® in Germany|
|2006||Medigene acquired British biotechnology company Avidex Limited|
|2006||Medigene’s product Veregen® became the first FDA approved biopharmaceutical of a German biotech company in the USA|
|2012-14||Medigene made strategic repositioning through sale of Eligard®, EndoTAG® and RhuDex®|
|2014||Focus on immuno-oncology by strategic acquisition of Trianta Immunotherapies GmbH (now Medigene Immunotherapies GmbH)|
|2015||Medigene initiated first proprietary DC vaccine clinical trial|
|2016||Medigene’s DC trial entered phase II|
|2016||Medigene signed development partnership to develop and characterize new TCR-Ts for bluebird bio Inc., USA|
|2018||Start of the first, own clinical TCR-T trial with MDG1011|
|2018||Expansion of the bluebird bio partnership|
|2019||Medigene signed research and development partnership for innovative cellular therapies in Asia with Cytovant/Roivant|